Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.75 |
| ▸ | CTSK | P43235 | 12/20 | 0.75 |
| ▸ | CTSB | P07858 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763891 | 1.00 | CTSS (0.75) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3758014 | 0.93 | CTSK (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5564249 | 0.88 | CTSS (0.75) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5564256 | 0.88 | CTSS (0.75) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6746907 | 0.88 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3762221 | 0.88 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5732504 | 0.87 | CTSS (0.77) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5732509 | 0.87 | CTSS (0.77) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL15989226 | 0.87 | CTSS (0.77) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL1979805 | 0.86 | CTSS (0.72) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN-LA ROCHE, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | CTSS 3355/4885CTSK 2354/4885CTSB 2508/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885CTSK 8/4885CTSB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.